MAIA Biotech is a targeted therapy, immuno-oncology company focused on the development and commercialization of first-in-class drugs. $MAIA
Joined June 2020
- Tweets 394
- Following 254
- Followers 609
- Likes 28
291 Photos and videos
Momentum continues in the expansion of the THIO-101 trial. MAIA Biotechnology has activated its second U.S. clinical site for the ongoing Phase 2 expansion trial evaluating ateganosine as the 3L treatment in advanced #NSCLC.
Read more: bit.ly/3PVZA0O $MAIA
1
5
275
MAIA Biotechnology provided a patient enrollment update for its pivotal Phase 3 THIO-104 trial evaluating ateganosine in advanced #NSCLC.
The company is targeting up to 100 patients by year-end and expects an interim analysis in 2027.
Read more: bit.ly/43ekpYo $MAIA
2
8
270
MAIA CEO Vlad Vitoc and Director Stan Smith increased their ownership positions through open market purchases of MAIA common stock.
The continued investments underscore confidence in MAIA's telomere-targeting immuno-oncology platform.
Learn more: bit.ly/4eitt4v $MAIA
1
12
331
Over the weekend at #ASCO26, MAIA CEO Vlad Vitoc and Dr. Tomasz Jankowski presented the company's THIO-104 Trial in Progress poster.
The level of engagement surrounding MAIA's clinical programs remains encouraging. Learn more about THIO-104: bit.ly/4amOSam $MAIA
8
315
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at #ASCO2026.
Read more: bit.ly/4amOSam $MAIA @ASCO
1
1
5
368
MAIA Biotechnology is advancing its NSCLC clinical program across multiple stages, including U.S. expansion and continued long-term survival follow-up in Phase 2.
Read the update from Diamond Equity Research: bit.ly/4dCZt1U $MAIA
4
336
.@Diamondequities released an updated research note on MAIA Biotechnology highlighting continued progress across the company’s clinical development programs, including the ongoing THIO-101 Phase 2 expansion trial in advanced NSCLC.
Read more: bit.ly/3RLkKyW $MAIA
1
7
539
Roughly 50,000 NSCLC patients progress to third-line of treatment each year in the U.S., underscoring the need for new therapeutic approaches.
MAIA’s THIO-101 study is evaluating a telomere-targeting investigational therapy in this population. bit.ly/4sDCbOK $MAIA
1
10
521
Phase 2 data from MAIA’s THIO-101 study show measures of efficacy, including disease control, response rates, and survival, above historical standard-of-care benchmarks in heavily pre-treated NSCLC. More: bit.ly/4sDCbOK $MAIA
1
8
624
ICYMI: MAIA Biotechnology has activated its first U.S. clinical site for the Phase 2 THIO-101 expansion study, with additional U.S. sites planned in 2026, marking a key milestone for the company.
Learn more: bit.ly/4sDCbOK $MAIA
1
10
775
Today, MAIA Biotechnology announced expansion of its Phase 2 THIO-101 trial with the activation of its first U.S. clinical site at Summit Medical Group in New Jersey, evaluating ateganosine in third-line NSCLC patients.
Read more: bit.ly/4sDCbOK $MAIA
1
5
399
New interview in @BioTuesdays: MAIA Biotechnology’s CEO Vlad Vitoc, MD, MBA, outlines its telomere-targeting approach and highlights Phase 2 results for ateganosine in NSCLC.
• 17.8 months overall survival
• 88% disease control rate
Read here: bit.ly/3Q5NRfO $MAIA
1
7
331
MAIA expects recent $33M capital raise to fully support its ongoing Phase 3 trial of its lead investigational therapy ateganosine, as a treatment for #NSCLC.
Read more: bit.ly/41TAhP3 $MAIA
1
5
268
Coverage from @PharmaNowGlobal highlights MAIA Biotechnology’s ongoing Phase 2 THIO-101 trial in NSCLC. Eight patients treated with ateganosine followed by cemiplimab exceeded 2-year survival after prior checkpoint inhibitor failure.
Learn more: bit.ly/3PKurwV $MAIA
1
3
311
MAIA Biotechnology presented updated THIO-101 Phase 2 trial results at #ELCC2026. Eight patients with NSCLC treated with ateganosine Libtayo surpassed 2-year survival following prior therapies.
Subscribers can read the @NobleCapMkts report here: bit.ly/4sfOCQT $MAIA
1
1
4
407
MAIA Biotechnology shared data from the Phase 2 THIO-101 trial in NSCLC at #ELCC2026. Eight patients treated with ateganosine sequenced with cemiplimab achieved overall survival exceeding 2 years after prior therapies.
Read more from @cure_today: bit.ly/4sclz0z $MAIA
1
4
283
MAIA is advancing ateganosine, a potential first-in-class telomere-targeting agent. It is designed to disrupt telomeres in cancer cells and work in sequence with checkpoint inhibitors.
Now in a Phase 3 NSCLC trial, with interim analyses ahead: bit.ly/4103jfF $MAIA
1
2
195
From #ELCC2026 in Copenhagen: MAIA’s poster presentation highlighted Phase 2 THIO-101 data in #NSCLC showing overall survival beyond two years for eight patients treated with ateganosine sequenced with cemiplimab.
Read more: bit.ly/4tjXZ2S $MAIA
3
252
Ateganosine utilizes a dual mechanism of action with direct telomere-targeting and immune system activation. While we advance our lead candidate in NSCLC, R&D continues on our 2nd-generation pipeline for multiple tumor types. bit.ly/4bgzrR1 $MAIA
2
6
473
Ateganosine continues to deliver unprecedented efficacy in third-line NSCLC. Interim Phase 2 data show a median overall survival of 17.8 months - 3x the current chemotherapy standard. Learn more: bit.ly/4bgzrR1 $MAIA
1
6
430